|
|
Volumn 21, Issue 2, 2003, Pages 115-116
|
|
Lymphoma market turf war imminent, pending Bexxar approval.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
IBRITUMOMAB TIUXETAN;
MONOCLONAL ANTIBODY;
ARTICLE;
COMMERCIAL PHENOMENA;
DRUG APPROVAL;
ECONOMIC ASPECT;
ECONOMICS;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
MARKETING;
NONHODGKIN LYMPHOMA;
RADIOIMMUNOTHERAPY;
RECURRENT DISEASE;
UNITED STATES;
ANTIBODIES, MONOCLONAL;
COMMERCE;
DRUG APPROVAL;
ECONOMIC COMPETITION;
HUMANS;
LYMPHOMA, NON-HODGKIN;
MARKETING;
RADIOIMMUNOTHERAPY;
RECURRENCE;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 0041786614
PISSN: 10870156
EISSN: None
Source Type: Journal
DOI: 10.1038/nbt0203-115 Document Type: Article |
|
Times cited : (2)
|
|
References (0)
|
